MK-8628
Total Payments
$87,790
Transactions
27
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $10,586 | 6 | 0 |
| 2018 | $1.36 | 1 | 0 |
| 2017 | $77,202 | 20 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $87,790 | 27 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase IB Dose Exploration Trial with MK-8628, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal BET Proteins, in Subjects with Selected Advanced Solid Tumors | Merck Sharp & Dohme Corporation | $81,840 | 0 |
| A Phase IB Trial with MK-8628, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal BET Proteins, in Patients with Selected Hematologic Malignancies | Merck Sharp & Dohme Corporation | $4,200 | 0 |
| A Phase 3, Safety and Efficacy Study of Boceprevir,Peginterferon Alfa-2a,ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects Protocol No. P07755 also known as MK-3034-040-00 | Merck Sharp & Dohme Corporation | $1,750 | 0 |
Top Doctors Receiving Payments for MK-8628
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Nashville, TN | $87,790 | 27 |
Ad
Manufacturing Companies
- Merck Sharp & Dohme Corporation $87,790
Product Information
- Type Drug
- Total Payments $87,790
- Total Doctors 0
- Transactions 27
About MK-8628
MK-8628 is a drug associated with $87,790 in payments to 0 healthcare providers, recorded across 27 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2017 to 2019. In 2019, $10,586 was paid across 6 transactions to 0 doctors.
The most common payment nature for MK-8628 is "Unspecified" ($87,790, 100.0% of total).
MK-8628 is associated with 3 research studies, including "A Phase IB Dose Exploration Trial with MK-8628, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal BET Proteins, in Subjects with Selected Advanced Solid Tumors" ($81,840).